Medicure Valuation
| MPH Stock | CAD 1.12 0.02 1.75% |
Today, the firm appears to be overvalued. Medicure secures a last-minute Real Value of C$1.0 per share. The latest price of the firm is C$1.12. Our model forecasts the value of Medicure from analyzing the firm fundamentals such as Current Valuation of 8.57 M, profit margin of (0.13) %, and Return On Equity of -0.18 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Medicure's valuation include:
Overvalued
Today
Please note that Medicure's price fluctuation is abnormally volatile at this time. Calculation of the real value of Medicure is based on 3 months time horizon. Increasing Medicure's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Medicure stock is determined by what a typical buyer is willing to pay for full or partial control of Medicure. Since Medicure is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Medicure Stock. However, Medicure's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.12 | Real 1.0 | Hype 1.16 |
The intrinsic value of Medicure's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Medicure's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Medicure helps investors to forecast how Medicure stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Medicure more accurately as focusing exclusively on Medicure's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Medicure's intrinsic value based on its ongoing forecasts of Medicure's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Medicure's closest peers.
Medicure Cash |
|
Medicure Total Value Analysis
Medicure is now estimated to have takeover price of 8.57 M with market capitalization of 11.69 M, debt of 8.9 M, and cash on hands of 45.7 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Medicure fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
8.57 M | 11.69 M | 8.9 M | 45.7 M |
Medicure Investor Information
About 27.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.68. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Medicure recorded a loss per share of 0.33. The entity had not issued any dividends in recent years. The firm had 1:15 split on the 2nd of November 2012. Based on the measurements of operating efficiency obtained from Medicure's historical financial statements, Medicure is not in a good financial situation at this time. It has a very high probability of going through financial hardship in March.Medicure Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Medicure has an asset utilization ratio of 73.81 percent. This indicates that the Company is making C$0.74 for each dollar of assets. An increasing asset utilization means that Medicure is more efficient with each dollar of assets it utilizes for everyday operations.Medicure Profitability Analysis
Based on the measurements of profitability obtained from Medicure's financial statements, Medicure may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in March. Profitability indicators assess Medicure's ability to earn profits and add value for shareholders.Net Loss | First Reported 2002-06-30 | Previous Quarter -786 K | Current Value -1.4 M | Quarterly Volatility 7.9 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.84 | 0.69 |
|
|
For Medicure profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Medicure to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Medicure utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Medicure's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Medicure over time as well as its relative position and ranking within its peers.
Medicure Earnings per Share Projection vs Actual
By analyzing Medicure's earnings estimates, investors can diagnose different trends across Medicure's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Medicure is based on EPS before non-recurring items and includes expenses related to employee stock options.Medicure Ownership Allocation
The market capitalization of Medicure is C$11.69 Million. Medicure holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Medicure Profitability Analysis
The company reported the revenue of 21.91 M. Net Loss for the year was (1.04 M) with profit before overhead, payroll, taxes, and interest of 12.77 M.About Medicure Valuation
Our relative valuation model uses a comparative analysis of Medicure. We calculate exposure to Medicure's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Medicure's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 15.1 M | 9.1 M | |
| Pretax Profit Margin | (0.03) | (0.03) | |
| Operating Profit Margin | (0.11) | (0.12) | |
| Net Loss | (0.04) | (0.04) | |
| Gross Profit Margin | 0.69 | 0.84 |
Additional Tools for Medicure Stock Analysis
When running Medicure's price analysis, check to measure Medicure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medicure is operating at the current time. Most of Medicure's value examination focuses on studying past and present price action to predict the probability of Medicure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medicure's price. Additionally, you may evaluate how the addition of Medicure to your portfolios can decrease your overall portfolio volatility.